Glenmark ne September quarter ke results announce kar diye hain. Company ne **₹42,473 million** ka revenue dikhaya hai aur profit **₹2,638 million** raha hai, lekin US ke ek legal settlement ne numbers ko thoda daba diya hai.
Results ka breakdown
Is baar Glenmark ke numbers mein ek bada twist hai. Revenue toh ₹42,473.28 million par stable raha, lekin bottom-line par US mein chal rahe ek antitrust lawsuit ka asar dikha. Company ko Humana, Inc. ke saath settlement ke liye ₹2,838.75 million ka ek bada exceptional charge dena pada.
Kya tension lene wali baat hai?
Bilkul nahi! Agar aap is one-time legal kharche ko hata kar dekhein, toh company ka underlying operating profit ₹6,221.63 million raha hai. Iska matlab saaf hai ki pharma business ka core operations abhi bhi majboot chal raha hai. Company ne clear kiya hai ki ye settlement sirf case khatam karne ke liye hai, iska matlab ye nahi ki koi galti maani gayi hai.
Aage kya track karein?
Investors ko ab sirf core margins par focus karna chahiye kyunki ye legal charge non-recurring hai, yaani bar-bar nahi aayega. Agle kuch quarters mein margins ki stability hi stock ki asli taqat dikhayegi. Filhal toh ye bas ek legal speed-breaker jaisa hai jo business ki lambi race ko slow nahi karega.